Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,579 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cutaneous Clear all

Conditions: Gingival Recession
Interventions: Tunnel + AlloDerm, Tunnel + Novomatrix; Procedure
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Sjogren-Larsson Syndrome
Interventions: ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Omaha, Nebraska

Conditions: Cutaneous Melanoma
Interventions: Medical Chart Review, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasm Metastasis, Melanoma
Interventions: Diphenylcyclopropenone (DPCP); Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: High-Risk Melanoma
Interventions: gp100:209-217 (210M), Montanide ISA-51, Imiquimod; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Pembrolizumab, Quality-of-Life Assessment, Therapeutic Tumor Infiltrating Lymphocytes; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Burns
Interventions: Regional nerve block, Catheter; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions: Enpatoran, Placebo, Standard of care (SoC); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 12 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: biologic sample preservation procedure, cytology specimen collection procedure; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2040
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Large Cell Lymphoma
Interventions: SGN-30; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 9 more

Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema, Atopic Dermatitis
Interventions: Blood draw, skin biopsy or urine collection; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Skin Laxity
Interventions: Dermal Cooling System; Device
Lead sponsor: R2 Dermatology; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Folsom, California • Fremont, California

Conditions: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Chronic Lymphocytic Leukemia
Interventions: Deoxycoformycin (DCF); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma of the Extremity, Recurrent Sarcoma of the Extremity, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions: FACT Complex-targeting Curaxin CBL0137; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma
Interventions: AMG 232, Trametinib, Dabrafenib; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 2 more

Conditions: Melanoma, Unresectable Melanoma, Advanced Melanoma
Interventions: Ceritinib, Trametinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Infections, Chickenpox
Interventions: Sorivudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Wallingford, Connecticut

Conditions: Mycosis Fungoides, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Peripheral T-Cell, Lymphomas: Non-Hodgkin Cutaneous Lymphoma
Interventions: Total Skin Electron Beam Therapy (TSEBT); Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: SCAR
Interventions: Blood or Saliva; Other
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: Not listed
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Ulcer, Diabetic Polyneuropathy
Interventions: personal dermal thermometer (DT), Device; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Tucson, Georgia

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis
Interventions: secukinumab 150 mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more

Conditions: Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Sezary Syndrome, Refractory Mycosis Fungoides, Refractory Mycosis Fungoides and Sezary Syndrome, Refractory Sezary Syndrome, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Magrolimab, Mogamulizumab, Positron Emission Tomography, Punch Biopsy; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 18
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 12 more

Conditions: Dermal and Epidermal Pigmented Lesions
Interventions: 755nm Alexandrite Laser; Device
Lead sponsor: Cynosure, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
Interventions: Internet Mobile Technology, Internet-Based Intervention, Questionnaire Administration, Supportive Care, Informational Intervention; Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more

Search by objective public record fields.

Root Coverage Comparing an Allograft to a Bovine Xenograft

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma

Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Dermal Cryotherapy in Patients Undergoing Abdominoplasty

A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides

An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate

Dermal Thermometry and Self-Care of High Risk Diabetic Patients

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Evaluation of the 755nm Alexandrite for the Treatment of Epidermal and Dermal Pigmented Lesions

Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study